

Biography

Sungwon Lim
ImpriMed, Inc.

Sungwon Lim is a bioengineer/entrepreneur with 18 years of collective experiences in academia and pharmaceutical and biotech industries.

- BS, KAIST, Chemical and Biomolecular Engineering
- MS, KAIST, Chemical and Biomolecular Engineering (Prof. Sang Yup Lee)
- MTM (Master of Translational Medicine), UC Berkeley-UCSF Joint Bioengineering Program
- PhD, Stanford University, Bioengineering (Prof. Jennifer Cochran)
- 4 years at ViroMed, Ltd. (Now Helixmith, Ltd.)
- 2.5 years at ImpriMed, Inc.

He founded ImpriMed, Inc. with a strong motivation to innovate a way to help cancer patients who need an effective treatment 'today', by optimizing and personalizing drug treatment options that are currently available in our medical cabinet. His team is building a comparative oncology platform to develop and prove new cell-based, functional precision medicine technologies in the veterinary oncology space first, at a significantly higher speed with by far more comprehensive data than the human oncology space, and then translate the collected database into human cancer care.

- Founded in 2017
- Raised \$4M Seed round with Draper Associates, Stanford Healthcare, StartX, Plug and Play Ventures, etc.
- Working with 101 veterinary oncologists at 81 hospitals in 26 states in the US